end-stage knee joint non-inflammatory disease
Conditions
Interventions
Intravenous and topical TXA group:Intravenous and topical application of tranexamic acid
Intravenous TXA group:Intravenous application of tranexamic acid
Topical TXA group:Topical application of tranexamic acid
Sponsors
West China hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. more than 18 years old; 2. with a diagnosis of osteoarthritis; 3. undergoing elective, unilateral, primary TKA; 4. preoperative blood routine test and blood coagulation at normal status.
Exclusion criteria
Exclusion criteria: 1. with a diagnosis of traumatic knee osteoarthritis, rheumatoid arthritis and other secondary osteoarthritis; 2. undergoing the second, bilateral or revision total knee arthroplasty; 3. tranexamic acid, o enoxaparin and apixaban use contraindication; 4. preoperative and/or postoperative long-term use of anticoagulant drugs such as warfarin, aspirin; 5. liver and kidney dysfunction, hemophilia, myocardial ischemia and history of VTE, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| postoperative blood loss;Volume and rate of postoperative autologous blood retransfusion;Incidence of postoperative VTE; | — |
Secondary
| Measure | Time frame |
|---|---|
| swelling degree of the operated knee;Knee Society Score;Visual Analogue Scale (VAS) Pain Score;operative time;length of hospital stay;Patient satisfaction; | — |
Countries
China
Contacts
Public ContactShen Bin
Outcome results
None listed